Search results
GENMAB A/S/S (OTCMKTS:GMXAY) and LianBio (NASDAQ:LIAN) Critical Contrast
ETF DAILY NEWS· 3 days agoLianBio (NASDAQ:LIAN – Get Free Report) and GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Hits New 1-Year High Following Analyst Upgrade
ETF DAILY NEWS· 1 day agoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) hit a new 52-week high on Wednesday after Royal Bank of Canada raised their price target on the stock from $77.00 to $82.00 ...
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from Needham & Company LLC
ETF DAILY NEWS· 2 days agoNeedham & Company LLC reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note published on Tuesday morning, Benzinga reports. They currently ...
Amid big Bayer shakeup, drugmaker loses Berkeley-based biotech chief - San Francisco Business Times
The Business Journals· 3 days agoJens Vogel, who as global head of biotech led Bayer AG's push into cell therapy manufacturing from...
Lighthouse Investment Partners LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)
ETF DAILY NEWS· 3 days agoLighthouse Investment Partners LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent disclosure with ...
UBS Reaffirms 'Buy' for ALX Oncology stock, Highlights Promising ASPEN-07 Study Results By...
Investing.com· 4 days agoOn Monday, UBS reaffirmed its confidence in ALX Oncology (NASDAQ:ALXO) stock maintaining a Buy...
Ultragenyx director Sanders Corazon sells $71,390 in company stock By Investing.com
Investing.com· 4 days agoThe shares were sold at a price of $41.10 each. Sanders Corazon, who serves as a director of...
BVF Inc. IL Makes New $31.78 Million Investment in Annexon, Inc. (NASDAQ:ANNX)
ETF DAILY NEWS· 1 day agoBVF Inc. IL purchased a new position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 4 days agoFDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., June 9, 2024 TOKYO and CAMBRIDGE,
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Analysts
ETF DAILY NEWS· 5 days agoDianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned an average...
